Spots Global Cancer Trial Database for Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Official Title: A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
Study ID: NCT05068752
Conditions
Study Description
Brief Summary: The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
Contact Details
Name: Erkut Borazanci, MD, MS
Affiliation: HonorHealth Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
